Annexon (NASDAQ:ANNX) President and CEO Doug Love outlined the company's late-stage pipeline and regulatory plans during a ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. In 2024, Healio covered several stories about trials ...

PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing disruptive non-viral vectorized gene therapies with minimally-invasive delivery technology, has reported the ...

Please provide your email address to receive an email when new articles are posted on . For the fourth consecutive year, Prevent Blindness has declared Dec. 2 to 8 as Geographic Atrophy Awareness Week ...

A novel outcome measure for geographic atrophy, the Geographic Atrophy Weighted-by-Acuity Index, aligned with best-corrected visual acuity, showing better correlation and predictive accuracy than the ...

What is IZERVAY™?IZERVAY (avacincaptad pegol intravitreal solution) is a prescription eye injection, used to treat geographic atrophy (GA), the advanced form of dry age-related macular degeneration ...

Ryan Haumschild, PharmD, MS, MBA, opens a discussion surrounding the disease landscape of geographic atrophy. Ryan Haumschild, PharmD, MS, MBA: Hello, and welcome to this AJMC® Peer Exchange®program ...

ACP is an investigational complement C5 inhibitor that is designed to decrease the activation of inflammasomes and the formation of membrane attack complex. The Food and Drug Administration (FDA) has ...

I’m 79 now, and my doctor diagnosed me with age-related macular degeneration (AMD) in 2008. Over the past 15 years, I’ve developed wet AMD in my left eye and geographic atrophy (GA) in both eyes. I ...

—Certain imaging biomarkers and demographic factors are associated with geographic atrophy growth rate and may guide the selection of patients for the use of newer therapeutics. As the population ...

September 2, 2008 — A gene variant that protects against geographic atrophy has been identified by investigators from several institutions in China and the United States. The variant appears to ...

Randomized trials of two FDA-approved intravitreal complement inhibitor injections showed that they slowed the progression of geographic atrophy, but failed to demonstrate functional benefits at 24 ...